Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631514 | 1.00 | MET (0.55) | METROCK2FLT3HSPB1 | |
| SCHEMBL29992379 | 0.87 | MAP4K1 (0.48) | METROCK2FLT3 | |
| SCHEMBL20588567 | 0.87 | MAP4K1 (0.48) | METROCK2FLT3 | |
| SCHEMBL30844464 | 0.86 | KMT2A (0.52) | METROCK2 | |
| SCHEMBL3484554 | 0.86 | KMT2A (0.52) | METROCK2 | |
| SCHEMBL20589193 | 0.85 | CYP1A2 (0.48) | METROCK2FLT3 | |
| SCHEMBL4251520 | 0.83 | MET (0.50) | METROCK2FLT3 | |
| SCHEMBL2198300 | 0.82 | TRPA1 (0.68) | METHSPB1 | |
| SCHEMBL30310247 | 0.82 | FLT3 (0.48) | METROCK2FLT3HSPB1 | |
| SCHEMBL1946687 | 0.82 | FLT3 (0.48) | METROCK2FLT3HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-25 | — | — | US | disclosed |
| CN-116283916-B | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| CN-116283916-A | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| US-20220324869-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-10-13 | — | — | US | disclosed |
| US-11427578-B1 | Substituted pyrrolopyridine-derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-30 | — | — | US | disclosed |
| CN-112457295-B | Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-26 | — | — | CN | disclosed |
| EP-4029862-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-110520416-B | Polysubstituted pyridone derivative, preparation method and medical application thereof | 北京越之康泰生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112047941-B | Compound and application thereof in preparing medicine for treating diseases caused by high expression of Flt3/c-Met kinase | 温州医科大学 | 2021-10-29 | — | — | CN | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060241104-A1 | Oxalamide derivatives as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-26 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MET 721/4885ROCK2 395/4885FLT3 126/4885 |
| US-20060241104-A1 | Oxalamide derivatives as kinase inhibitors | PDK1, OAT, PDXK | MET 337/4885ROCK2 1347/4885FLT3 254/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | MET 2109/4885ROCK2 433/4885FLT3 246/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MET 721/4885ROCK2 395/4885FLT3 126/4885 |
| US-20220324869-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | MET, MERTK, AXL | MET 1/4885ROCK2 373/4885FLT3 6/4885 |
| US-11427578-B1 | Substituted pyrrolopyridine-derivatives | MAP3K4, MAP4K4, MAP4K3 | MET 4142/4885ROCK2 723/4885FLT3 462/4885 |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | MET, MERTK, AXL | MET 1/4885ROCK2 373/4885FLT3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.